BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-65. [PMID: 12506171 DOI: 10.1200/jco.2003.10.066] [Cited by in Crossref: 1199] [Cited by in F6Publishing: 307] [Article Influence: 66.6] [Reference Citation Analysis]
Number Citing Articles
1 Ranieri G, Ferrari C, Di Palo A, Marech I, Porcelli M, Falagario G, Ritrovato F, Ramunni L, Fanelli M, Rubini G, Gadaleta CD. Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study. Int J Mol Sci 2017;18:E1458. [PMID: 28684680 DOI: 10.3390/ijms18071458] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
2 Marques I, Araújo A, de Mello RA. Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives. World J Gastroenterol. 2013;19:7955-7971. [PMID: 24307789 DOI: 10.3748/wjg.v19.i44.7955] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
3 Kristin E, Endarti D, Khoe LC, Taroeno-Hariadi KW, Trijayanti C, Armansyah A, Sastroasmoro S. Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia. Asian Pac J Cancer Prev 2021;22:1921-6. [PMID: 34181352 DOI: 10.31557/APJCP.2021.22.6.1921] [Reference Citation Analysis]
4 Ramma W, Ahmed A. Is inflammation the cause of pre-eclampsia? Biochem Soc Trans 2011;39:1619-27. [PMID: 22103497 DOI: 10.1042/BST20110672] [Cited by in Crossref: 74] [Cited by in F6Publishing: 26] [Article Influence: 8.2] [Reference Citation Analysis]
5 Suenaga M, Mizunuma N, Kobayashi K, Shinozaki E, Matsusaka S, Chin K, Kuboki Y, Ichimura T, Ozaka M, Ogura M. Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab. Med Oncol. 2010;27:807-814. [PMID: 19697164 DOI: 10.1007/s12032-009-9289-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
6 Tahover E, Uziely B, Salah A, Temper M, Peretz T, Hubert A. Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol 2013;30:327. [PMID: 23254964 DOI: 10.1007/s12032-012-0327-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
7 Ahmadizar F, Onland-Moret NC, de Boer A, Liu G, Maitland-van der Zee AH. Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One 2015;10:e0136324. [PMID: 26331473 DOI: 10.1371/journal.pone.0136324] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
8 Chen CT, Yamaguchi H, Lee HJ, Du Y, Lee HH, Xia W, Yu WH, Hsu JL, Yen CJ, Sun HL, Wang Y, Yeh ET, Hortobagyi GN, Hung MC. Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase. Mol Cancer Ther 2011;10:1327-36. [PMID: 21610170 DOI: 10.1158/1535-7163.MCT-10-1117] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
9 Torok S, Rezeli M, Kelemen O, Vegvari A, Watanabe K, Sugihara Y, Tisza A, Marton T, Kovacs I, Tovari J, Laszlo V, Helbich TH, Hegedus B, Klikovits T, Hoda MA, Klepetko W, Paku S, Marko-Varga G, Dome B. Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors. Theranostics 2017;7:400-12. [PMID: 28042343 DOI: 10.7150/thno.16767] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
10 Rossi L, Veltri E, Zullo A, Zoratto F, Colonna M, Longo F, Mottolese M, Giannarelli D, Ruco L, Marchetti P. Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. Onco Targets Ther. 2013;6:1761-1769. [PMID: 24348051 DOI: 10.2147/ott.s43828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
11 Carden CP, Larkin JM, Rosenthal MA. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol. 2008;10:624-630. [PMID: 18539884 DOI: 10.1215/15228517-2008-010] [Cited by in Crossref: 63] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
12 Flexman ML, Vlachos F, Kim HK, Sirsi SR, Huang J, Hernandez SL, Johung TB, Gander JW, Reichstein AR, Lampl BS, Wang A, Borden MA, Yamashiro DJ, Kandel JJ, Hielscher AH. Monitoring early tumor response to drug therapy with diffuse optical tomography. J Biomed Opt 2012;17:016014. [PMID: 22352664 DOI: 10.1117/1.JBO.17.1.016014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
13 Ki MK, Jeoung MH, Choi JR, Rho SS, Kwon YG, Shim H, Chung J, Hong HJ, Song BD, Lee S. Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro. Oncogene 2013;32:5449-57. [PMID: 23644659 DOI: 10.1038/onc.2013.156] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
14 Gherman A, Căinap C, Constantin AM, Cetean S, Căinap SS. Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab. Clujul Med 2017;90:377-84. [PMID: 29151784 DOI: 10.15386/cjmed-745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Munemoto Y, Kato T, Hata T, Denda T, Morita Y, Inukai M, Kunieda K, Nagata N, Kurachi K, Ina K, Ooshiro M, Shimoyama T, Baba H, Oba K, Sakamoto J, Mishima H. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol 2015;26:1427-33. [PMID: 25908603 DOI: 10.1093/annonc/mdv197] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
16 Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007;130:691-703. [PMID: 17719546 DOI: 10.1016/j.cell.2007.06.054] [Cited by in Crossref: 696] [Cited by in F6Publishing: 594] [Article Influence: 49.7] [Reference Citation Analysis]
17 Vo KT, Matthay KK, DuBois SG. Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. Clin Sarcoma Res 2016;6:9. [PMID: 27274393 DOI: 10.1186/s13569-016-0049-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
18 Botrel TEA, Clark LGO, Paladini L, Clark OAC. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2016;16:677. [PMID: 27558497 DOI: 10.1186/s12885-016-2734-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 8.4] [Reference Citation Analysis]
19 Pataky RE, Beca J, Tran D, Dai WF, Dvorani E, Isaranuwatchai W, Peacock S, Alvi R, Cheung WY, Earle CC, Gavura S, Chan KKW. Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces. MDM Policy Pract 2021;6:23814683211021060. [PMID: 34212111 DOI: 10.1177/23814683211021060] [Reference Citation Analysis]
20 Huang H, Zheng Y, Zhu J, Zhang J, Chen H, Chen X. An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients. PLoS One 2014;9:e89960. [PMID: 24599121 DOI: 10.1371/journal.pone.0089960] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
21 Bertuccio CA. Relevance of VEGF and nephrin expression in glomerular diseases. J Signal Transduct 2011;2011:718609. [PMID: 21808734 DOI: 10.1155/2011/718609] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
22 Battaglin F, Puccini A, Intini R, Schirripa M, Ferro A, Bergamo F, Lonardi S, Zagonel V, Lenz HJ, Loupakis F. The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Rev Anticancer Ther 2018;18:251-66. [PMID: 29338550 DOI: 10.1080/14737140.2018.1428092] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
23 Temraz S, Mukherji D, Shamseddine A. Sequencing of treatment in metastatic colorectal cancer: where to fit the target. World J Gastroenterol 2014;20:1993-2004. [PMID: 24616571 DOI: 10.3748/wjg.v20.i8.1993] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
24 Niu G, Chen X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets. 2010;11:1000-1017. [PMID: 20426765 DOI: 10.2174/138945010791591395] [Cited by in Crossref: 188] [Cited by in F6Publishing: 140] [Article Influence: 17.1] [Reference Citation Analysis]
25 Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008;246:837-842. [PMID: 18286296 DOI: 10.1007/s00417-008-0774-y] [Cited by in Crossref: 111] [Cited by in F6Publishing: 81] [Article Influence: 8.5] [Reference Citation Analysis]
26 Prat A, Casado E, Cortés J. New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol 2007;13:5857-66. [PMID: 17990351 DOI: 10.3748/wjg.v13.i44.5857] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
27 Myskowski PL, Halpern AC. Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer. Curr Allergy Asthma Rep 2008;8:63-8. [PMID: 18377777 DOI: 10.1007/s11882-008-0012-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
28 Schiffmann LM, Brunold M, Liwschitz M, Goede V, Loges S, Wroblewski M, Quaas A, Alakus H, Stippel D, Bruns CJ, Hallek M, Kashkar H, Hacker UT, Coutelle O. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition. Br J Cancer 2017;116:600-8. [PMID: 28141797 DOI: 10.1038/bjc.2017.13] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
29 Lee SY, Oh SC. Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. Biomed Res Int. 2016;2016:7590245. [PMID: 27127793 DOI: 10.1155/2016/7590245] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
30 Schad F, Axtner J, Kröz M, Matthes H, Steele ML. Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations. Integr Cancer Ther 2018;17:41-51. [PMID: 29444603 DOI: 10.1177/1534735416681641] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
31 Dean E, El-Helw L, Hasan J. Targeted therapies in epithelial ovarian cancer. Cancers (Basel) 2010;2:88-113. [PMID: 24281034 DOI: 10.3390/cancers2010088] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
32 Gamulescu MA, Radeck V, Lustinger B, Fink B, Helbig H. Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration. Int Ophthalmol 2010;30:261-6. [PMID: 19633973 DOI: 10.1007/s10792-009-9318-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
33 Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, Kumar SK, Kimlinger TK, Northfelt DW, Flynn PJ, Jaeckle KA, Kaufmann TJ, Buckner JC. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res 2013;19:4816-23. [PMID: 23833308 DOI: 10.1158/1078-0432.CCR-13-0708] [Cited by in Crossref: 91] [Cited by in F6Publishing: 44] [Article Influence: 11.4] [Reference Citation Analysis]
34 Fuloria J. Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer. Onco Targets Ther 2012;5:133-42. [PMID: 22930641 DOI: 10.2147/OTT.S31412] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Cisterna BA, Kamaly N, Choi WI, Tavakkoli A, Farokhzad OC, Vilos C. Targeted nanoparticles for colorectal cancer. Nanomedicine (Lond) 2016;11:2443-56. [PMID: 27529192 DOI: 10.2217/nnm-2016-0194] [Cited by in Crossref: 66] [Cited by in F6Publishing: 45] [Article Influence: 13.2] [Reference Citation Analysis]
36 Han K, Peyret T, Marchand M, Quartino A, Gosselin NH, Girish S, Allison DE, Jin J. Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol 2016;78:341-51. [PMID: 27329360 DOI: 10.1007/s00280-016-3079-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 5.6] [Reference Citation Analysis]
37 Sugimoto S, Katano K, Kanazawa A, Yoshimura H, Kidani A, Takeda H, Makino M, Ozaki N, Tanaka T, Ikeguchi M. Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients. J Exp Clin Cancer Res 2009;28:109. [PMID: 19664225 DOI: 10.1186/1756-9966-28-109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
38 Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C, Bachet JB, Portales F, Vaillant JN, Ychou M, Rougier P. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer 2009;9:347. [PMID: 19785749 DOI: 10.1186/1471-2407-9-347] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
39 Jang HJ, Kim BJ, Kim JH, Kim HS. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials. Oncotarget. 2017;8:73009-73016. [PMID: 29069844 DOI: 10.18632/oncotarget.20314] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
40 Barni S, Cabiddu M, Guarneri P, Lonati V, Petrelli F. The risk for anemia with targeted therapies for solid tumors. Oncologist 2012;17:715-24. [PMID: 22531357 DOI: 10.1634/theoncologist.2012-0024] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
41 Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol. 2007;25:4033-4042. [PMID: 17827451 DOI: 10.1200/jco.2007.11.3985] [Cited by in Crossref: 106] [Cited by in F6Publishing: 32] [Article Influence: 7.6] [Reference Citation Analysis]
42 Souza FF, Smith A, Araujo C, Jagannathan J, Johnston C, O'Regan K, Shinagare A, Ramaiya N. New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know. Cancer Imaging 2014;14:26. [PMID: 25608887 DOI: 10.1186/1470-7330-14-26] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
43 Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M, Wen PY. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 2007;9:354-63. [PMID: 17452651 DOI: 10.1215/15228517-2007-006] [Cited by in Crossref: 90] [Cited by in F6Publishing: 69] [Article Influence: 6.4] [Reference Citation Analysis]
44 Ryanne Wu R, Lindenberg PA, Slack R, Noone AM, Marshall JL, He AR. Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer. 2009;40:101-108. [PMID: 19921473 DOI: 10.1007/s12029-009-9104-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
45 Dewdney A, Cunningham D, Barbachano Y, Chau I. Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. Br J Cancer. 2012;106:1718-1721. [PMID: 22531628 DOI: 10.1038/bjc.2012.152] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
46 Bauditz J, Lochs H. Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol. 2007;13:5979-5984. [PMID: 18023086 DOI: 10.3748/wjg.13.5979] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
47 Brose KM, Lee AY. Cancer-associated thrombosis: prevention and treatment. Curr Oncol 2008;15:S58-67. [PMID: 18231650 DOI: 10.3747/co.2008.177] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
48 Meulenbeld HJ, Creemers GJ. First-line treatment strategies for elderly patients with metastatic colorectal cancer. Drugs Aging 2007;24:223-38. [PMID: 17362050 DOI: 10.2165/00002512-200724030-00004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
49 Yildiz R, Benekli M, Ozkan M, Alkis N, Berk V, Kaplan MA, Ciltas A, Karaca H, Durnali AG, Coskun U, Dikilitas M, Sevinc A, Dane F, Yetisyigit T, Dogu GG, Buyukberber S. Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. J Cancer Res Clin Oncol 2012;138:1845-52. [PMID: 22722713 DOI: 10.1007/s00432-012-1264-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
50 Choi YI, Lee SH, Ahn BK, Baek SU, Park SJ, Kim YS, Shin SH. Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin). Cancer Res Treat 2008;40:33-5. [PMID: 19688063 DOI: 10.4143/crt.2008.40.1.33] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
51 Haddad AJ, Bani Hani M, Pawlik TM, Cunningham SC. Colorectal liver metastases. Int J Surg Oncol 2011;2011:285840. [PMID: 22312501 DOI: 10.1155/2011/285840] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
52 Klautke G, Fietkau R. Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review. Int J Colorectal Dis 2007;22:457-65. [PMID: 17072624 DOI: 10.1007/s00384-006-0204-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
53 Gill S, Thomas RR, Goldberg RM. New targeted therapies in gastrointestinal cancers. Curr Treat Options Oncol. 2003;4:393-403. [PMID: 12941199 DOI: 10.1007/s11864-003-0040-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
54 Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther. 2008;7:3670-3684. [PMID: 19074844 DOI: 10.1158/1535-7163.mct-08-0715] [Cited by in Crossref: 218] [Cited by in F6Publishing: 106] [Article Influence: 18.2] [Reference Citation Analysis]
55 Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2012;17:15-25. [PMID: 22234633 DOI: 10.1634/theoncologist.2011-0249] [Cited by in Crossref: 147] [Cited by in F6Publishing: 121] [Article Influence: 16.3] [Reference Citation Analysis]
56 Naithani N, Atal AT, Tilak TVSVGK, Vasudevan B, Misra P, Sinha S. Precision medicine: Uses and challenges. Med J Armed Forces India 2021;77:258-65. [PMID: 34305277 DOI: 10.1016/j.mjafi.2021.06.020] [Reference Citation Analysis]
57 Chebotareva N, Bobkova I, Lysenko L, Moiseev S. Urinary Markers of Podocyte Dysfunction in Chronic Glomerulonephritis. Adv Exp Med Biol 2021;1306:81-99. [PMID: 33959907 DOI: 10.1007/978-3-030-63908-2_6] [Reference Citation Analysis]
58 Piatek C, O'Connell CL, Liebman HA. Treating venous thromboembolism in patients with cancer. Expert Rev Hematol 2012;5:201-9. [PMID: 22475288 DOI: 10.1586/ehm.11.86] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
59 Fuso Nerini I, Cesca M, Bizzaro F, Giavazzi R. Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. Chin J Cancer 2016;35:61. [PMID: 27357621 DOI: 10.1186/s40880-016-0123-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
60 Pavlidis ET, Pavlidis TE. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review. World J Gastroenterol. 2013;19:5051-5060. [PMID: 23964138 DOI: 10.3748/wjg.v19.i31.5051] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 47] [Article Influence: 8.4] [Reference Citation Analysis]
61 Kirstein MM, Lange A, Prenzler A, Manns MP, Kubicka S, Vogel A. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist. 2014;19:1156-1168. [PMID: 25326159 DOI: 10.1634/theoncologist.2014-0032] [Cited by in Crossref: 69] [Cited by in F6Publishing: 54] [Article Influence: 9.9] [Reference Citation Analysis]
62 Cidón EU. The challenge of metastatic colorectal cancer. Clin Med Insights Oncol 2010;4:55-60. [PMID: 20711244 DOI: 10.4137/cmo.s5214] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
63 Newsome BW, Ernstoff MS. The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Br J Clin Pharmacol 2008;66:6-19. [PMID: 18503606 DOI: 10.1111/j.1365-2125.2008.03187.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
64 Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N. Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res 2015;7:133-43. [PMID: 26082660 DOI: 10.2147/CMAR.S77400] [Cited by in Crossref: 43] [Cited by in F6Publishing: 16] [Article Influence: 7.2] [Reference Citation Analysis]
65 Cheng CL, Hou HA, Jhuang JY, Lin CW, Chen CY, Tang JL, Chou WC, Tseng MH, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF. High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes. Br J Cancer 2011;105:975-82. [PMID: 21878936 DOI: 10.1038/bjc.2011.340] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
66 Ilic I, Jankovic S, Ilic M. Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis. PLoS One 2016;11:e0161912. [PMID: 27579775 DOI: 10.1371/journal.pone.0161912] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
67 Mukherjee A, Westwell AD, Bradshaw TD, Stevens MF, Carmichael J, Martin SG. Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study. Br J Cancer 2005;92:350-8. [PMID: 15655539 DOI: 10.1038/sj.bjc.6602338] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
68 Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer. 2009;100:1704-1719. [PMID: 19436303 DOI: 10.1038/sj.bjc.6605061] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 6.3] [Reference Citation Analysis]
69 Ladabaum U, Mannalithara A, Brill JV, Levin Z, Bundorf KM. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare. Am J Gastroenterol 2018;113:1836-47. [PMID: 29904156 DOI: 10.1038/s41395-018-0106-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
70 Lai XX, Xu RA, Yu-Ping L, Yang H. Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther 2016;9:2421-8. [PMID: 27143937 DOI: 10.2147/OTT.S96156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
71 Strickler JH, Hurwitz HI. Palliative treatment of metastatic colorectal cancer: what is the optimal approach? Curr Oncol Rep 2014;16:363. [PMID: 24293074 DOI: 10.1007/s11912-013-0363-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
72 Sun X, Suo J, Yan J. Immunotherapy in human colorectal cancer: Challenges and prospective. World J Gastroenterol. 2016;22:6362-6372. [PMID: 27605872 DOI: 10.3748/wjg.v22.i28.6362] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
73 Bendell JC, Sauri T, Gracián AC, Alvarez R, López-López C, García-Alfonso P, Hussein M, Miron ML, Cervantes A, Montagut C, Vivas CS, Bessudo A, Plezia P, Moons V, Andel J, Bennouna J, van der Westhuizen A, Samuel L, Rossomanno S, Boetsch C, Lahr A, Franjkovic I, Heil F, Lechner K, Krieter O, Hurwitz H; McCAVE Study Group. The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). Oncologist 2020;25:e451-9. [PMID: 32162804 DOI: 10.1634/theoncologist.2019-0291] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
74 Meadows KL, Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2012;2:a006577. [PMID: 23028128 DOI: 10.1101/cshperspect.a006577] [Cited by in Crossref: 132] [Cited by in F6Publishing: 105] [Article Influence: 14.7] [Reference Citation Analysis]
75 Senger DR. Vascular endothelial growth factor: much more than an angiogenesis factor. Mol Biol Cell. 2010;21:377-379. [PMID: 20124007 DOI: 10.1091/mbc.E09-07-0591] [Cited by in Crossref: 58] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
76 O’Connell JT, Sugimoto H, Cooke VG, MacDonald BA, Mehta AI, LeBleu VS, Dewar R, Rocha RM, Brentani RR, Resnick MB. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci USA. 2011;108:16002-16007. [PMID: 21911392 DOI: 10.1073/pnas.1109493108] [Cited by in Crossref: 206] [Cited by in F6Publishing: 215] [Article Influence: 20.6] [Reference Citation Analysis]
77 Armaly Z, Jadaon JE, Jabbour A, Abassi ZA. Preeclampsia: Novel Mechanisms and Potential Therapeutic Approaches. Front Physiol 2018;9:973. [PMID: 30090069 DOI: 10.3389/fphys.2018.00973] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 19.0] [Reference Citation Analysis]
78 Wehland M, Bauer J, Magnusson NE, Infanger M, Grimm D. Biomarkers for anti-angiogenic therapy in cancer. Int J Mol Sci 2013;14:9338-64. [PMID: 23629668 DOI: 10.3390/ijms14059338] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
79 García-Foncillas J, Díaz-Rubio E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Transl Oncol 2010;12:533-42. [PMID: 20709651 DOI: 10.1007/s12094-010-0551-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
80 López R, Salgado M, Reboredo M, Grande C, Méndez JC, Jorge M, Romero C, Quintero G, de la Cámara J, Candamio S. A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer. Br J Cancer 2010;103:1536-41. [PMID: 20940719 DOI: 10.1038/sj.bjc.6605938] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
81 Guan M, Zhou YP, Sun JL, Chen SC. Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res Int 2015;2015:428169. [PMID: 26075239 DOI: 10.1155/2015/428169] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
82 Losordo DW, Henry TD, Davidson C, Sup Lee J, Costa MA, Bass T, Mendelsohn F, Fortuin FD, Pepine CJ, Traverse JH, Amrani D, Ewenstein BM, Riedel N, Story K, Barker K, Povsic TJ, Harrington RA, Schatz RA;  ACT34-CMI Investigators. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109:428-436. [PMID: 21737787 DOI: 10.1161/circresaha.111.245993] [Cited by in Crossref: 353] [Cited by in F6Publishing: 174] [Article Influence: 35.3] [Reference Citation Analysis]
83 Corrò C, Dutoit V, Koessler T. Emerging Trends for Radio-Immunotherapy in Rectal Cancer. Cancers (Basel) 2021;13:1374. [PMID: 33803620 DOI: 10.3390/cancers13061374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Lordick F, Peschel C, Siewert JR. Antibody-based targeted therapy for gastric cancer. Gastric Cancer 2005;8:206-8. [PMID: 16328593 DOI: 10.1007/s10120-005-0345-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
85 Sereno M, Brunello A, Chiappori A, Barriuso J, Casado E, Belda C, de Castro J, Feliu J, González-Barón M. Cardiac toxicity: old and new issues in anti-cancer drugs. Clin Transl Oncol 2008;10:35-46. [PMID: 18208791 DOI: 10.1007/s12094-008-0150-8] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
86 Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010;125:490-493. [PMID: 20097409 DOI: 10.1016/j.thromres.2009.12.023] [Cited by in Crossref: 187] [Cited by in F6Publishing: 126] [Article Influence: 17.0] [Reference Citation Analysis]
87 Abajo A, Boni V, Lopez I, Gonzalez-Huarriz M, Bitarte N, Rodriguez J, Zarate R, Bandres E, Garcia-Foncillas J. Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. Br J Cancer 2012;107:287-90. [PMID: 22699823 DOI: 10.1038/bjc.2012.242] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
88 Brown NS, Streeter EH, Jones A, Harris AL, Bicknell R. Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma. Br J Cancer. 2005;92:1696-1701. [PMID: 15841086 DOI: 10.1038/sj.bjc.6602522] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
89 Kim DD, Eng C. The current state of targeted agents in rectal cancer. Int J Surg Oncol 2012;2012:406830. [PMID: 22675625 DOI: 10.1155/2012/406830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
90 Gelmini S, Mangoni M, Serio M, Romagnani P, Lazzeri E. The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. J Endocrinol Invest 2008;31:809-19. [PMID: 18997494 DOI: 10.1007/BF03349262] [Cited by in Crossref: 73] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
91 Yu Y, Fang L, Sun D. Biodistribution of HuCC49DeltaCH2-beta-galactosidase in colorectal cancer xenograft model. Int J Pharm 2010;386:208-15. [PMID: 19944136 DOI: 10.1016/j.ijpharm.2009.11.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
92 Bruera G, Santomaggio A, Cannita K, Baldi PL, Tudini M, De Galitiis F, Mancini M, Marchetti P, Antonucci A, Ficorella C, Ricevuto E. "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer 2010;10:567. [PMID: 20958992 DOI: 10.1186/1471-2407-10-567] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
93 Rodrigues CA, Ferrarotto R, Kalil Filho R, Novis YA, Hoff PM. Venous thromboembolism and cancer: a systematic review. J Thromb Thrombolysis 2010;30:67-78. [PMID: 20140479 DOI: 10.1007/s11239-010-0441-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
94 Maharaj AS, Saint-Geniez M, Maldonado AE, D'Amore PA. Vascular endothelial growth factor localization in the adult. Am J Pathol 2006;168:639-48. [PMID: 16436677 DOI: 10.2353/ajpath.2006.050834] [Cited by in Crossref: 207] [Cited by in F6Publishing: 173] [Article Influence: 13.8] [Reference Citation Analysis]
95 Sun W. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol. 2012;5:63. [PMID: 23057939 DOI: 10.1186/1756-8722-5-63] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 6.2] [Reference Citation Analysis]
96 Su EN, Cringle SJ, McAllister IL, Yu DY. An experimental study of VEGF induced changes in vasoactivity in pig retinal arterioles and the influence of an anti-VEGF agent. BMC Ophthalmol 2012;12:10. [PMID: 22642643 DOI: 10.1186/1471-2415-12-10] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
97 Chen XL, Lei YH, Liu CF, Yang QF, Zuo PY, Liu CY, Chen CZ, Liu YW. Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis. PLoS One 2013;8:e66721. [PMID: 23818962 DOI: 10.1371/journal.pone.0066721] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
98 Degirmenci M, Karaca B, Gorumlu G, Durusoy R, Demir Piskin G, Bozkurt MT, Cirak Y, Tunali D, Karabulut B, Sanli UA. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. Med Oncol. 2010;27:585-591. [PMID: 19526201 DOI: 10.1007/s12032-009-9253-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
99 Vaniotis G, Moffett S, Sulea T, Wang N, Elahi SM, Lessard E, Baardsnes J, Perrino S, Durocher Y, Frystyk J, Massie B, Brodt P. Enhanced anti-metastatic bioactivity of an IGF-TRAP re-engineered to improve physicochemical properties. Sci Rep 2018;8:17361. [PMID: 30478273 DOI: 10.1038/s41598-018-35407-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
100 Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K;  Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1-42. [PMID: 31203527 DOI: 10.1007/s10147-019-01485-z] [Cited by in Crossref: 282] [Cited by in F6Publishing: 228] [Article Influence: 141.0] [Reference Citation Analysis]
101 Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg. 2007;11:1057-1077. [PMID: 17530336 DOI: 10.1007/s11605-006-0061-3] [Cited by in Crossref: 151] [Cited by in F6Publishing: 123] [Article Influence: 10.8] [Reference Citation Analysis]
102 Jin KT, Chen B, Liu YY, Lan HU, Yan JP. Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. Cancer Cell Int 2021;21:83. [PMID: 33522929 DOI: 10.1186/s12935-021-01763-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
103 Su Y, Yang WB, Li S, Ye ZJ, Shi HZ, Zhou Q. Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One 2012;7:e35629. [PMID: 22539986 DOI: 10.1371/journal.pone.0035629] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
104 Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther 2010;9:176-82. [PMID: 20009575 DOI: 10.4161/cbt.9.3.10635] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 4.0] [Reference Citation Analysis]
105 Segal E, Pan H, Ofek P, Udagawa T, Kopecková P, Kopecek J, Satchi-Fainaro R. Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One 2009;4:e5233. [PMID: 19381291 DOI: 10.1371/journal.pone.0005233] [Cited by in Crossref: 86] [Cited by in F6Publishing: 69] [Article Influence: 7.2] [Reference Citation Analysis]
106 Vitolo D, Ciocci L, Deriu G, Spinelli S, Cortese S, Masuelli L, Morrone S, Filice MJ, Coloni GF, Natali PG, Baroni CD. Laminin alpha2 chain-positive vessels and epidermal growth factor in lung neuroendocrine carcinoma: a model of a novel cooperative role of laminin-2 and epidermal growth factor in vessel neoplastic invasion and metastasis. Am J Pathol 2006;168:991-1003. [PMID: 16507913 DOI: 10.2353/ajpath.2006.041310] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
107 Kavitha CV, Agarwal C, Agarwal R, Deep G. Asiatic acid inhibits pro-angiogenic effects of VEGF and human gliomas in endothelial cell culture models. PLoS One 2011;6:e22745. [PMID: 21826202 DOI: 10.1371/journal.pone.0022745] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
108 Rangwala F, Bendell JC, Kozloff MF, Arrowood CC, Dellinger A, Meadows J, Tourt-Uhlig S, Murphy J, Meadows KL, Starr A, Broderick S, Brady JC, Cushman SM, Morse MA, Uronis HE, Hsu SD, Zafar SY, Wallace J, Starodub AN, Strickler JH, Pang H, Nixon AB, Hurwitz HI. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Invest New Drugs 2014;32:700-9. [PMID: 24711126 DOI: 10.1007/s10637-014-0089-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
109 Zhao T, Wang X, Xu T, Xu X, Liu Z. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget. 2017;8:51492-51506. [PMID: 28881662 DOI: 10.18632/oncotarget.18190] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
110 Marín-Pozo JF, Duarte-Pérez JM, Sánchez-Rovira P. Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience. Medicine (Baltimore) 2016;95:e3623. [PMID: 27175672 DOI: 10.1097/MD.0000000000003623] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
111 Dai F, Shu L, Bian Y, Wang Z, Yang Z, Chu W, Gao S. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials. Clin Drug Investig. 2013;33:779-788. [PMID: 23979925 DOI: 10.1007/s40261-013-0125-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
112 Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009;101:1033-8. [PMID: 19789532 DOI: 10.1038/sj.bjc.6605259] [Cited by in Crossref: 128] [Cited by in F6Publishing: 100] [Article Influence: 10.7] [Reference Citation Analysis]
113 Fang L, Battisti RF, Cheng H, Reigan P, Xin Y, Shen J, Ross D, Chan KK, Martin EW Jr, Wang PG, Sun D. Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates. J Med Chem 2006;49:6290-7. [PMID: 17034135 DOI: 10.1021/jm060647f] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
114 Muehlenbachs A, Mutabingwa TK, Edmonds S, Fried M, Duffy PE. Hypertension and maternal-fetal conflict during placental malaria. PLoS Med 2006;3:e446. [PMID: 17105340 DOI: 10.1371/journal.pmed.0030446] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 6.1] [Reference Citation Analysis]
115 Shamimi-Noori S, Gonsalves CF, Shaw CM. Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data.Semin Intervent Radiol. 2017;34:145-166. [PMID: 28579683 DOI: 10.1055/s-0037-1602712] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
116 Tabana Y, Okoye IS, Siraki A, Elahi S, Barakat KH. Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis. Front Oncol 2021;11:628138. [PMID: 33747948 DOI: 10.3389/fonc.2021.628138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Ronnekleiv-Kelly SM, Burkhart RA, Pawlik TM. Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. Surg Oncol 2016;25:190-9. [PMID: 27566022 DOI: 10.1016/j.suronc.2016.05.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
118 Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A, Vamvakas L, Kotsakis A, Agelaki S, Diamandidou E. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer. 2007;7:91. [PMID: 17537235 DOI: 10.1186/1471-2407-7-91] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 4.9] [Reference Citation Analysis]
119 Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist 2010;15:819-25. [PMID: 20688807 DOI: 10.1634/theoncologist.2009-0317] [Cited by in Crossref: 75] [Cited by in F6Publishing: 55] [Article Influence: 6.8] [Reference Citation Analysis]
120 Salmon AH, Neal CR, Bates DO, Harper SJ. Vascular endothelial growth factor increases the ultrafiltration coefficient in isolated intact Wistar rat glomeruli. J Physiol 2006;570:141-56. [PMID: 16239266 DOI: 10.1113/jphysiol.2005.099184] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
121 Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S. The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review. PLoS One 2013;8:e51780. [PMID: 23349675 DOI: 10.1371/journal.pone.0051780] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
122 Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, Yoshino T, Boku N, Fujimori T, Itabashi M, Koinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Yamaguchi N, Tanaka T, Kotake K, Sugihara K;  Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1-34. [PMID: 28349281 DOI: 10.1007/s10147-017-1101-6] [Cited by in Crossref: 400] [Cited by in F6Publishing: 276] [Article Influence: 100.0] [Reference Citation Analysis]
123 Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-18. [DOI: 10.1038/nrclinonc.2009.110] [Cited by in Crossref: 257] [Cited by in F6Publishing: 207] [Article Influence: 21.4] [Reference Citation Analysis]
124 Mei-Zahav M, Gendler Y, Bruckheimer E, Prais D, Birk E, Watad M, Goldschmidt N, Soudry E. Topical Propranolol Improves Epistaxis Control in Hereditary Hemorrhagic Telangiectasia (HHT): A Randomized Double-Blind Placebo-Controlled Trial. J Clin Med 2020;9:E3130. [PMID: 32998220 DOI: 10.3390/jcm9103130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB, Jiang YY. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol 2010;66:813-21. [PMID: 20401474 DOI: 10.1007/s00228-010-0815-4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
126 Rosati G, Cordio S, Aprile G, Butera A, Avallone A, Di Lucca G, De Pauli F, Parra HS, Reggiardo G, Bordonaro R. Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study. Invest New Drugs. 2012;30:1978-1983. [PMID: 21769636 DOI: 10.1007/s10637-011-9721-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
127 Longo C, Patanarut A, George T, Bishop B, Zhou W, Fredolini C, Ross MM, Espina V, Pellacani G, Petricoin EF 3rd, Liotta LA, Luchini A. Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers. PLoS One 2009;4:e4763. [PMID: 19274087 DOI: 10.1371/journal.pone.0004763] [Cited by in Crossref: 77] [Cited by in F6Publishing: 64] [Article Influence: 6.4] [Reference Citation Analysis]
128 Gratzinger D, Advani R, Zhao S, Talreja N, Tibshirani RJ, Shyam R, Horning S, Sehn LH, Farinha P, Briones J, Lossos IS, Gascoyne RD, Natkunam Y. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). Br J Haematol 2010;148:235-44. [PMID: 19821819 DOI: 10.1111/j.1365-2141.2009.07942.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
129 Totzeck M, Mincu RI, Rassaf T. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients. J Am Heart Assoc 2017;6:e006278. [PMID: 28862931 DOI: 10.1161/JAHA.117.006278] [Cited by in Crossref: 50] [Cited by in F6Publishing: 24] [Article Influence: 12.5] [Reference Citation Analysis]
130 Goda JS, Pachpor T, Basu T, Chopra S, Gota V. Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers. Indian J Med Res 2016;143:145-59. [PMID: 27121513 DOI: 10.4103/0971-5916.180201] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
131 Aparicio J, Esposito F, Serrano S, Falco E, Escudero P, Ruiz-Casado A, Manzano H, Fernandez-Montes A. Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease. J Clin Med 2020;9:E3889. [PMID: 33265959 DOI: 10.3390/jcm9123889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
132 Tea MN, Poonnoose SI, Pitson SM. Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma. Cancers (Basel) 2020;12:E111. [PMID: 31906280 DOI: 10.3390/cancers12010111] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
133 Abajo A, Bitarte N, Zarate R, Boni V, Lopez I, Gonzalez-Huarriz M, Rodriguez J, Bandres E, Garcia-Foncillas J. Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. World J Gastroenterol 2012;18:637-45. [PMID: 22363134 DOI: 10.3748/wjg.v18.i7.637] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
134 Ladabaum U, Ferrandez A, Lanas A. Cost-effectiveness of colorectal cancer screening in high-risk Spanish patients: use of a validated model to inform public policy. Cancer Epidemiol Biomarkers Prev. 2010;19:2765-2776. [PMID: 20810603 DOI: 10.1158/1055-9965.epi-10-0530] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
135 Macedo FI, Makarawo T. Colorectal hepatic metastasis: Evolving therapies. World J Hepatol 2014;6:453-63. [PMID: 25067997 DOI: 10.4254/wjh.v6.i7.453] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
136 Madu CO, Wang S, Madu CO, Lu Y. Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment. J Cancer 2020;11:4474-94. [PMID: 32489466 DOI: 10.7150/jca.44313] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
137 Giakoustidis A, Neofytou K, Khan A, Mudan S. Addition of bevacizumab to preoperative chemotherapy for colorectal liver metastases does not increase perioperative morbidity and mortality. Hepat Oncol 2014;1:363-75. [PMID: 30190972 DOI: 10.2217/hep.14.17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
138 Schirin-Sokhan R, Winograd R, Roderburg C, Bubenzer J, do Ó NC, Guggenberger D, Hecker H, Trautwein C, Tischendorf JJ. Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound. World J Gastroenterol 2012;18:541-5. [PMID: 22363120 DOI: 10.3748/wjg.v18.i6.541] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
139 Nishino M, Hatabu H, Sholl LM, Ramaiya NH. Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. Radiographics 2017;37:1371-87. [PMID: 28898185 DOI: 10.1148/rg.2017170015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 9.5] [Reference Citation Analysis]
140 Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford) 2013;15:106-15. [PMID: 23297721 DOI: 10.1111/j.1477-2574.2012.00558.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
141 Field K, Michael M, Leong T. Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 2008;68:299-317. [PMID: 18257608 DOI: 10.2165/00003495-200868030-00004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
142 Bauditz J, Lochs H. Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol 2007;13:5979-84. [PMID: 18023086 DOI: 10.3748/wjg.v13.45.5979] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
143 Luchini A, Fredolini C, Espina BH, Meani F, Reeder A, Rucker S, Petricoin EF 3rd, Liotta LA. Nanoparticle technology: addressing the fundamental roadblocks to protein biomarker discovery. Curr Mol Med 2010;10:133-41. [PMID: 20196732 DOI: 10.2174/156652410790963268] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
144 Turner DC, Navid F, Daw NC, Mao S, Wu J, Santana VM, Neel M, Rao B, Willert JR, Loeb DM, Harstead KE, Throm SL, Freeman BB 3rd, Stewart CF. Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing. Clin Cancer Res 2014;20:2783-92. [PMID: 24637635 DOI: 10.1158/1078-0432.CCR-13-2364] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 3.9] [Reference Citation Analysis]
145 Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep. 2012;14:277-284. [PMID: 22532266 DOI: 10.1007/s11912-012-0238-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
146 Kim LA, D'Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol 2012;181:376-9. [PMID: 22749677 DOI: 10.1016/j.ajpath.2012.06.006] [Cited by in Crossref: 90] [Cited by in F6Publishing: 63] [Article Influence: 10.0] [Reference Citation Analysis]
147 Mocellin S, Baretta Z, Roqué I Figuls M, Solà I, Martin-Richard M, Hallum S, Bonfill Cosp X. Second-line systemic therapy for metastatic colorectal cancer. Cochrane Database Syst Rev 2017;1:CD006875. [PMID: 28128439 DOI: 10.1002/14651858.CD006875.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
148 Qu CY, Zheng Y, Zhou M, Zhang Y, Shen F, Cao J, Xu LM. Value of bevacizumab in treatment of colorectal cancer: A meta-analysis. World J Gastroenterol 2015;21:5072-80. [PMID: 25945023 DOI: 10.3748/wjg.v21.i16.5072] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
149 Bashir B, Snook AE. Immunotherapy regimens for metastatic colorectal carcinomas. Hum Vaccin Immunother 2018;14:250-4. [PMID: 29083978 DOI: 10.1080/21645515.2017.1397244] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
150 Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15:325-340. [PMID: 29508855 DOI: 10.1038/nrclinonc.2018.29] [Cited by in Crossref: 440] [Cited by in F6Publishing: 388] [Article Influence: 146.7] [Reference Citation Analysis]
151 Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013;15:106-115. [PMID: 23297721 DOI: 10.1111/j.1477-2574.2012.00558] [Reference Citation Analysis]
152 Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014;13:164-171. [PMID: 25069797 DOI: 10.1016/j.clcc.2014.06.001] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 9.4] [Reference Citation Analysis]
153 Belum VR, Cercek A, Sanz-Motilva V, Lacouture ME. Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management. Curr Treat Options Oncol 2013;14:389-404. [PMID: 23996476 DOI: 10.1007/s11864-013-0254-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
154 Wang K, Xu Q, Zhong H. The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae. Front Pharmacol 2020;11:625498. [PMID: 33519491 DOI: 10.3389/fphar.2020.625498] [Reference Citation Analysis]
155 Rad FH, Le Buanec H, Paturance S, Larcier P, Genne P, Ryffel B, Bensussan A, Bizzini B, Gallo RC, Zagury D. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A. 2007;104:2837-2842. [PMID: 17301234 DOI: 10.1073/pnas.0611022104] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 4.0] [Reference Citation Analysis]
156 Ma J, Chen CS, Blute T, Waxman DJ. Antiangiogenesis enhances intratumoral drug retention. Cancer Res. 2011;71:2675-2685. [PMID: 21447737 DOI: 10.1158/0008-5472.can-10-3242] [Cited by in Crossref: 37] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
157 Xiao B, Wang W, Zhang D. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. Onco Targets Ther 2018;11:5059-74. [PMID: 30174444 DOI: 10.2147/OTT.S166151] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
158 Ladha H, Pawar T, Gilbert MR, Mandel J, O-Brien B, Conrad C, Fields M, Hanna T, Loch C, Armstrong TS. Wound healing complications in brain tumor patients on Bevacizumab. J Neurooncol 2015;124:501-6. [PMID: 26298437 DOI: 10.1007/s11060-015-1868-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
159 Lorgis V, Maura G, Coppa G, Hassani K, Taillandier L, Chauffert B, Apetoh L, Ladoire S, Ghiringhelli F. Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. J Neurooncol 2012;107:351-8. [PMID: 22076449 DOI: 10.1007/s11060-011-0748-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
160 Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br J Cancer. 2011;105:44-52. [PMID: 21629245 DOI: 10.1038/bjc.2011.182] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
161 Schirin-Sokhan R, Winograd R, Roderburg C, Bubenzer J, do Ó NC, Guggenberger D, Hecker H, Trautwein C, Tischendorf JJ. Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound. World J Gastroenterol. 2012;18:541-545. [PMID: 22363120 DOI: 10.3748/wjg.v18.i6.541.] [Reference Citation Analysis]
162 Park LC, Lee HS, Shin SH, Park SJ, Park MI, Oh SY, Kwon HC, Baek JH, Choi YJ, Kang MJ. Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer. World J Gastroenterol. 2012;18:1104-1109. [PMID: 22416186 DOI: 10.3748/wjg.v18.i10.1104] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
163 Chirila C, Odom D, Devercelli G, Khan S, Sherif BN, Kaye JA, Molnár I, Sherrill B. Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer. Int J Colorectal Dis. 2012;27:623-634. [PMID: 22076612 DOI: 10.1007/s00384-011-1349-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
164 Mangoni M, Vozenin MC, Biti G, Deutsch E. Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead. Br J Cancer 2012;107:308-14. [PMID: 22691970 DOI: 10.1038/bjc.2012.236] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
165 Coutelle O, Schiffmann LM, Liwschitz M, Brunold M, Goede V, Hallek M, Kashkar H, Hacker UT. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours. Br J Cancer 2015;112:495-503. [PMID: 25562438 DOI: 10.1038/bjc.2014.629] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
166 Rodriguez J, Zarate R, Bandres E, Viudez A, Chopitea A, García-Foncillas J, Gil-Bazo I. Combining chemotherapy and targeted therapies in metastatic colorectal cancer. World J Gastroenterol 2007;13:5867-76. [PMID: 17990352 DOI: 10.3748/wjg.v13.i44.5867] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
167 Loupakis F, Bria E, Vaccaro V, Cuppone F, Milella M, Carlini P, Cremolini C, Salvatore L, Falcone A, Muti P. Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. J Exp Clin Cancer Res. 2010;29:58. [PMID: 20504361 DOI: 10.1186/1756-9966-29-58] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
168 Infante JR, Arkenau HT, Bendell JC, Rubin MS, Waterhouse D, Jones GT, Spigel DR, Lane CM, Hainsworth JD, Burris HA 3rd. Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial. Cancer Biol Ther 2013;14:340-6. [PMID: 23358470 DOI: 10.4161/cbt.23625] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
169 Zhao S, Huang J, Ye J. A fresh look at zebrafish from the perspective of cancer research. J Exp Clin Cancer Res 2015;34:80. [PMID: 26260237 DOI: 10.1186/s13046-015-0196-8] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 9.7] [Reference Citation Analysis]
170 Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010;21:1381-1389. [PMID: 20538785 DOI: 10.1681/asn.2010020167] [Cited by in Crossref: 141] [Cited by in F6Publishing: 56] [Article Influence: 12.8] [Reference Citation Analysis]
171 Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 2014;43:343-9. [PMID: 24622062 DOI: 10.1097/MPA.0000000000000095] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
172 des Guetz G, Uzzan B, Chouahnia K, Morère JF. Cardiovascular toxicity of anti-angiogenic drugs. Target Oncol 2011;6:197-202. [PMID: 22116787 DOI: 10.1007/s11523-011-0204-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
173 Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Chin K, Yamaguchi T. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. Drug Des Devel Ther 2015;9:1653-62. [PMID: 25834402 DOI: 10.2147/DDDT.S80449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
174 Saab R, Furman WL. Epidemiology and management options for colorectal cancer in children. Paediatr Drugs 2008;10:177-92. [PMID: 18454570 DOI: 10.2165/00148581-200810030-00006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
175 Unruh M, Grunow A, Gottstein C. Systemic coagulation parameters in mice after treatment with vascular targeting agents. Thromb J 2005;3:21. [PMID: 16336690 DOI: 10.1186/1477-9560-3-21] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
176 Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chévez-Barrios P. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007;91:804-7. [PMID: 17179168 DOI: 10.1136/bjo.2006.107912] [Cited by in Crossref: 150] [Cited by in F6Publishing: 112] [Article Influence: 10.0] [Reference Citation Analysis]
177 Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D, Tabernero J. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist. 2013;18:1004-1012. [PMID: 23881988 DOI: 10.1634/theoncologist.2013-0107] [Cited by in Crossref: 155] [Cited by in F6Publishing: 121] [Article Influence: 19.4] [Reference Citation Analysis]
178 Raig ET, Jones NB, Varker KA, Benniger K, Go MR, Biber JL, Lesinski GB, Carson WE 3rd. VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. J Interferon Cytokine Res 2008;28:553-61. [PMID: 18771339 DOI: 10.1089/jir.2008.0118] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
179 Tang JH, Zhao JH, Lu JW, Yan F, Qin JW, Xu B. Circulating levels of angiogenic cytokines in advanced breast cancer patients with system chemotherapy and their potential value in monitoring disease course. J Cancer Res Clin Oncol 2011;137:55-63. [PMID: 20221635 DOI: 10.1007/s00432-010-0859-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
180 Roberts JM, Rajakumar A. Preeclampsia and soluble fms-like tyrosine kinase 1. J Clin Endocrinol Metab 2009;94:2252-4. [PMID: 19584199 DOI: 10.1210/jc.2009-0945] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
181 Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C, Bréant C, Mathivet T, Larrivée B, Thomas JL. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med. 2010;16:420-428. [PMID: 20364125 DOI: 10.1038/nm.2131] [Cited by in Crossref: 222] [Cited by in F6Publishing: 176] [Article Influence: 20.2] [Reference Citation Analysis]
182 Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Target Oncol. 2017;12:599-610. [PMID: 28801849 DOI: 10.1007/s11523-017-0518-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 15.3] [Reference Citation Analysis]
183 Suenaga M, Fujimoto Y, Matsusaka S, Shinozaki E, Akiyoshi T, Nagayama S, Fukunaga Y, Oya M, Ueno M, Mizunuma N, Yamaguchi T. Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01). Onco Targets Ther 2015;8:1111-8. [PMID: 26056475 DOI: 10.2147/OTT.S83952] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
184 Magnussen AL, Rennel ES, Hua J, Bevan HS, Beazley Long N, Lehrling C, Gammons M, Floege J, Harper SJ, Agostini HT, Bates DO, Churchill AJ. VEGF-A165b is cytoprotective and antiangiogenic in the retina. Invest Ophthalmol Vis Sci 2010;51:4273-81. [PMID: 20237249 DOI: 10.1167/iovs.09-4296] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 4.7] [Reference Citation Analysis]
185 Fakih M. The role of targeted therapy in the treatment of advanced colorectal cancer. Curr Treat Options Oncol 2008;9:357-74. [PMID: 19238551 DOI: 10.1007/s11864-009-0089-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
186 Linkins LA. Management of venous thromboembolism in patients with cancer: role of dalteparin. Vasc Health Risk Manag 2008;4:279-87. [PMID: 18561503 DOI: 10.2147/vhrm.s2132] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
187 Bonifazi M, Rossi M, Moja L, Scigliano VD, Franchi M, La Vecchia C, Zocchetti C, Negri E. Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety. Oncologist. 2012;17:117-124. [PMID: 22210090 DOI: 10.1634/theoncologist.2011-0184] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
188 Kuderer NM, Lyman GH. Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thromb Res 2014;133 Suppl 2:S122-7. [PMID: 24862132 DOI: 10.1016/S0049-3848(14)50021-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
189 Bhaskar V, Zhang D, Fox M, Seto P, Wong MH, Wales PE, Powers D, Chao DT, Dubridge RB, Ramakrishnan V. A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med 2007;5:61. [PMID: 18042290 DOI: 10.1186/1479-5876-5-61] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
190 Xu R, Xu C, Liu C, Cui C, Zhu J. Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer. Onco Targets Ther. 2018;11:8605-8621. [PMID: 30584320 DOI: 10.2147/ott.s171724] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
191 Meyerhardt JA, Li L, Sanoff HK, Carpenter W, Schrag D. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol. 2012;30:608-615. [PMID: 22253466 DOI: 10.1200/jco.2011.38.9650] [Cited by in Crossref: 93] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
192 Macedo LT, da Costa Lima AB, Sasse AD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer. 2012;12:89. [PMID: 22414244 DOI: 10.1186/1471-2407-12-89] [Cited by in Crossref: 79] [Cited by in F6Publishing: 62] [Article Influence: 8.8] [Reference Citation Analysis]
193 Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist. 2010;15:1179-1191. [PMID: 21045188 DOI: 10.1634/theoncologist.2009-0155] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
194 Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134:1296-1310. [PMID: 18471507 DOI: 10.1053/j.gastro.2008.02.098] [Cited by in Crossref: 307] [Cited by in F6Publishing: 240] [Article Influence: 23.6] [Reference Citation Analysis]
195 Bupathi M, Ahn DH, Bekaii-Saab T. Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. Gastrointest Cancer 2016;6:21-30. [PMID: 28190957 DOI: 10.2147/GICTT.S97740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
196 Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007;13:223-30. [PMID: 17462954 DOI: 10.1016/j.molmed.2007.04.001] [Cited by in Crossref: 102] [Cited by in F6Publishing: 87] [Article Influence: 7.3] [Reference Citation Analysis]
197 Reynolds AR. Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response 2010;8:253-84. [PMID: 20877487 DOI: 10.2203/dose-response.09-049.Reynolds] [Cited by in Crossref: 64] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
198 Strijbos MH, Gratama JW, Kraan J, Lamers CH, den Bakker MA, Sleijfer S. Circulating endothelial cells in oncology: pitfalls and promises. Br J Cancer. 2008;98:1731-1735. [PMID: 18506173 DOI: 10.1038/sj.bjc.6604383] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 5.7] [Reference Citation Analysis]
199 Ulivi P, Marisi G, Passardi A. Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. Oncotarget 2016;7:46678-91. [PMID: 27081084 DOI: 10.18632/oncotarget.8712] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
200 Zuo PY, Chen XL, Liu YW, Xiao CL, Liu CY. Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis. PLoS One 2014;9:e102484. [PMID: 25025282 DOI: 10.1371/journal.pone.0102484] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
201 Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol. 2007;13:3806-3815. [PMID: 17657834 DOI: 10.3748/wjg.v13.i28.3806] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
202 Nandikolla AG, Rajdev L. Targeting angiogenesis in gastrointestinal tumors: current challenges. Transl Gastroenterol Hepatol 2016;1:67. [PMID: 28138633 DOI: 10.21037/tgh.2016.08.04] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
203 Koh YW, Park CS, Yoon DH, Suh C, Huh J. CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma. PLoS One 2014;9:e87066. [PMID: 24489836 DOI: 10.1371/journal.pone.0087066] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
204 Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res 2008;75:1-8. [PMID: 17553534 DOI: 10.1016/j.mvr.2007.04.009] [Cited by in Crossref: 162] [Cited by in F6Publishing: 135] [Article Influence: 11.6] [Reference Citation Analysis]
205 Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 2009;6:259-65. [PMID: 19390552 DOI: 10.1038/nrclinonc.2009.38] [Cited by in Crossref: 54] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
206 Noonan SA, Morrissey ME, Martin P, Biniecka M, Ó'Meachair S, Maguire A, Tosetto M, Nolan B, Hyland J, Sheahan K, O'Donoghue D, Mulcahy H, Fennelly D, O'Sullivan J. Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment. Oncotarget 2018;9:10536-48. [PMID: 29535825 DOI: 10.18632/oncotarget.24276] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
207 Paiva TF Jr, de Jesus VH, Marques RA, da Costa AA, de Macedo MP, Peresi PM, Damascena A, Rossi BM, Begnami MD, de Lima VC. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival. BMC Cancer 2015;15:643. [PMID: 26394830 DOI: 10.1186/s12885-015-1648-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
208 Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology 2014;121:936-45. [PMID: 24405740 DOI: 10.1016/j.ophtha.2013.10.037] [Cited by in Crossref: 49] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
209 Abel EJ, Wood CG. Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol. 2009;6:375-383. [PMID: 19528960 DOI: 10.1038/nrurol.2009.102] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
210 Brem S, Grossman SA, Carson KA, New P, Phuphanich S, Alavi JB, Mikkelsen T, Fisher JD; New Approaches to Brain Tumor Therapy CNS Consortium. Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro Oncol 2005;7:246-53. [PMID: 16053699 DOI: 10.1215/S1152851704000869] [Cited by in Crossref: 81] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
211 Oh SC, Park YY, Park ES, Lim JY, Kim SM, Kim SB, Kim J, Kim SC, Chu IS, Smith JJ, Beauchamp RD, Yeatman TJ, Kopetz S, Lee JS. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut 2012;61:1291-8. [PMID: 21997556 DOI: 10.1136/gutjnl-2011-300812] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 6.1] [Reference Citation Analysis]
212 Huang GC, Chen LJ, Liu HC, Chen YJ. Development of vitreous haemorrhage during treatment with bevacizumab for metastatic rectal cancer. Clin Drug Investig 2008;28:523-6. [PMID: 18598098 DOI: 10.2165/00044011-200828080-00007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
213 Xu WH, Ge YL, Li Q, Zhang X, Duan JH. Inhibitory effect of vascular endothelial growth factors-targeted small interfering RNA on proliferation of gastric cancer cells. World J Gastroenterol 2007;13:2044-7. [PMID: 17465445 DOI: 10.3748/wjg.v13.i14.2044] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
214 Ono M, Ito T, Kanai T, Murayama K, Koyama H, Maeno K, Mochizuki Y, Iesato A, Hanamura T, Okada T, Watanabe T, Ito K. Rapid tumor necrosis and massive hemorrhage induced by bevacizumab and paclitaxel combination therapy in a case of advanced breast cancer. Onco Targets Ther 2013;6:1393-8. [PMID: 24124381 DOI: 10.2147/OTT.S51164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
215 Mulder K, Koski S, Scarfe A, Chu Q, King K, Spratlin J. Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget 2010;1:515-29. [PMID: 21317448 DOI: 10.18632/oncotarget.101006] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
216 Sharan S, Woo S. Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities. Front Pharmacol 2015;6:33. [PMID: 25750626 DOI: 10.3389/fphar.2015.00033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
217 Chan DL, Pavlakis N, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, Segelov E. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. PLoS One. 2015;10:e0135599. [PMID: 26275292 DOI: 10.1371/journal.pone.0135599] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
218 Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist 2010;15:130-41. [PMID: 20139170 DOI: 10.1634/theoncologist.2009-0252] [Cited by in Crossref: 81] [Cited by in F6Publishing: 53] [Article Influence: 7.4] [Reference Citation Analysis]
219 Thomas AA, Rini BI, Campbell SC. Integration of surgery and systemic therapy in the management of metastatic renal cancer. Curr Urol Rep 2009;10:35-41. [PMID: 19116094 DOI: 10.1007/s11934-009-0008-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
220 Song Y, Lu H, Wang Q, Xiang R. Targeting Angiogenesis by Blocking the ATM-SerRS-VEGFA Pathway for UV-Induced Skin Photodamage and Melanoma Growth. Cancers (Basel) 2019;11:E1847. [PMID: 31766690 DOI: 10.3390/cancers11121847] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
221 Di Bartolomeo M, Pietrantonio F, Martinetti A, Buzzoni R, Gevorgyan A, Bajetta E. Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer. Drugs Aging 2011;28:83-91. [PMID: 21155618 DOI: 10.2165/11584710-000000000-00000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
222 Caulet M, Lecomte T, Bouché O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D. Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Clin Pharmacokinet 2016;55:1381-94. [PMID: 27312193 DOI: 10.1007/s40262-016-0406-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 7.8] [Reference Citation Analysis]
223 Sung CY, Son MW, Ahn TS, Jung DJ, Lee MS, Baek MJ. Expression of placenta growth factor in colorectal carcinomas. J Korean Soc Coloproctol 2012;28:315-20. [PMID: 23346511 DOI: 10.3393/jksc.2012.28.6.315] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
224 Frucht H, Stevens PD, Fogelman DR, Verna EC, Chen J, Chabot JA, Fine RL. Advances in the Genetic Screening, Work-up, and Treatment of Pancreatic Cancer. Curr Treat Options Gastroenterol. 2004;7:343-354. [PMID: 15345205 DOI: 10.1007/s11938-004-0047-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
225 El Bali M, Bakkach J, Bennani Mechita M. Colorectal Cancer: From Genetic Landscape to Targeted Therapy. J Oncol 2021;2021:9918116. [PMID: 34326875 DOI: 10.1155/2021/9918116] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Pories SE, Wulf GM. Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review. Breast Cancer (Dove Med Press) 2010;2:37-44. [PMID: 24367165 DOI: 10.2147/bctt.s6511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
227 Königsberg R, Maierhofer J, Steininger T, Kienzer G, Dittrich C. Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab. Radiol Oncol 2014;48:184-8. [PMID: 24991208 DOI: 10.2478/raon-2013-0083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
228 Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT, Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM, Drappatz J, Ciampa A, Folkman J, Kieran M, Wen PY. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol 2008;10:300-8. [PMID: 18403492 DOI: 10.1215/15228517-2008-005] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
229 Andre N, Schmiegel W. Chemoradiotherapy for colorectal cancer. Gut 2005;54:1194-202. [PMID: 16009693 DOI: 10.1136/gut.2004.062745] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
230 Zhao Z, Pelletier E, Barber B, Bhosle M, Wang S, Klingman D, Gao S. Major surgery in patients with metastatic colorectal cancer in Western europe. J Gastrointest Cancer 2012;43:456-61. [PMID: 22125088 DOI: 10.1007/s12029-011-9349-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
231 Rajabi M, Mousa SA. The Role of Angiogenesis in Cancer Treatment. Biomedicines 2017;5:E34. [PMID: 28635679 DOI: 10.3390/biomedicines5020034] [Cited by in Crossref: 188] [Cited by in F6Publishing: 124] [Article Influence: 47.0] [Reference Citation Analysis]
232 Wells EM, Nageswara Rao AA, Scafidi J, Packer RJ. Neurotoxicity of biologically targeted agents in pediatric cancer trials. Pediatr Neurol 2012;46:212-21. [PMID: 22490765 DOI: 10.1016/j.pediatrneurol.2012.02.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
233 Weberpals J, Jansen L, Haefeli WE, Hoffmeister M, Wolkewitz M, Herk-Sukel MPPV, Vissers PAJ, Brenner H. Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study. Sci Rep 2017;7:2911. [PMID: 28588274 DOI: 10.1038/s41598-017-02913-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
234 Stein JD, Newman-Casey PA, Kim DD, Nwanyanwu KH, Johnson MW, Hutton DW. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology. 2013;120:1835-1842. [PMID: 23642372 DOI: 10.1016/j.ophtha.2013.02.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
235 Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist. 2010;15:539-547. [PMID: 20511320 DOI: 10.1634/theoncologist.2009-0274] [Cited by in Crossref: 89] [Cited by in F6Publishing: 66] [Article Influence: 8.1] [Reference Citation Analysis]
236 Cremolini C, Schirripa M, Antoniotti C, Moretto R, Salvatore L, Masi G, Falcone A, Loupakis F. First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nat Rev Clin Oncol 2015;12:607-19. [PMID: 26215044 DOI: 10.1038/nrclinonc.2015.129] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 15.2] [Reference Citation Analysis]
237 Guan ZZ, Xu JM, Luo RC, Feng FY, Wang LW, Shen L, Yu SY, Ba Y, Liang J, Wang D, Qin SK, Wang JJ, He J, Qi C, Xu RH. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer 2011;30:682-9. [PMID: 21959045 DOI: 10.5732/cjc.011.10188] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 8.6] [Reference Citation Analysis]
238 Parekh M, Fendrick AM, Ladabaum U. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther 2008;27:697-712. [PMID: 18248653 DOI: 10.1111/j.1365-2036.2008.03632.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
239 Moehler M, Sprinzl MF, Abdelfattah M, Schimanski CC, Adami B, Godderz W, Majer K, Flieger D, Teufel A, Siebler J. Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol. 2009;15:449-456. [PMID: 19152449 DOI: 10.3748/wjg.15.449] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
240 Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 2008;10:355-60. [PMID: 18436627 DOI: 10.1215/15228517-2008-009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 50] [Article Influence: 5.2] [Reference Citation Analysis]
241 Bazo IG, González VC, Gutiérrez ÁA, Rodríguez JR, Fernández JAP, Gómez JDLC, Lizoain JLH, López JG. Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer. Clin Transl Oncol 2005;7:150-5. [DOI: 10.1007/bf02708752] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
242 Chen YX, Yang Q, Kuang JJ, Chen SY, Wei Y, Jiang ZM, Xie DR. Efficacy of adding bevacizumab in the first-line chemotherapy of metastatic colorectal cancer: evidence from seven randomized clinical trials. Gastroenterol Res Pract 2014;2014:594930. [PMID: 24971091 DOI: 10.1155/2014/594930] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
243 Parodi L, Pickering E, Cisar LA, Lee D, Soufi-Mahjoubi R. Utility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer. Arch Drug Inf 2008;1:97-106. [PMID: 19639031 DOI: 10.1111/j.1753-5174.2008.00014.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
244 Acar BT, Halili E, Acar S. The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization. Int Ophthalmol 2013;33:507-13. [PMID: 23404727 DOI: 10.1007/s10792-013-9732-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
245 Chan E, Goff LW, Cardin DB, Ancell K, Smith SJ, Whisenant JG, Ye F, Berlin JD. Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS. Invest New Drugs 2017;35:491-8. [PMID: 28353122 DOI: 10.1007/s10637-017-0458-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
246 Ahmed A, Ramma W. Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm? Br J Pharmacol 2015;172:1574-86. [PMID: 25303561 DOI: 10.1111/bph.12977] [Cited by in Crossref: 44] [Cited by in F6Publishing: 27] [Article Influence: 8.8] [Reference Citation Analysis]
247 Madan RA, Dahut WL. Angiogenesis inhibition in the treatment of prostate cancer. Anticancer Agents Med Chem 2009;9:1070-8. [PMID: 19719453 DOI: 10.2174/187152009789735035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
248 Oppelt P, Betbadal A, Nayak L. Approach to chemotherapy-associated thrombosis. Vasc Med 2015;20:153-61. [PMID: 25832603 DOI: 10.1177/1358863X14568705] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 5.4] [Reference Citation Analysis]
249 Yang X, Zhang H, Kong F, Wang G, Gu Q, Zhao Z, Li T, Ren M, Li Z, Guo Y. Effect of Huisheng oral solution on coagulation function in perioperative period in patients with primary lung cancer. J Thorac Dis 2017;9:1891-902. [PMID: 28839987 DOI: 10.21037/jtd.2017.06.64] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
250 Hickey R, Vouche M, Sze DY, Hohlastos E, Collins J, Schirmang T, Memon K, Ryu RK, Sato K, Chen R, Gupta R, Resnick S, Carr J, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Lewandowski RJ, Salem R. Cancer concepts and principles: primer for the interventional oncologist-part II. J Vasc Interv Radiol 2013;24:1167-88. [PMID: 23810312 DOI: 10.1016/j.jvir.2013.04.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
251 Abajo A, Rodriguez J, Bitarte N, Zarate R, Boni V, Ponz M, Chopitea A, Bandres E, Garcia-Foncillas J. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients. Br J Cancer 2010;103:1529-35. [PMID: 20940716 DOI: 10.1038/sj.bjc.6605908] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
252 Suenaga M, Mizunuma N, Shinozaki E, Matsusaka S, Ozaka M, Ogura M, Chin K, Yamaguchi T. Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab. Onco Targets Ther 2015;8:243-9. [PMID: 25670906 DOI: 10.2147/OTT.S75722] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
253 Bhargava S, Hotz B, Hines OJ, Reber HA, Buhr HJ, Hotz HG. Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer. J Gastrointest Surg 2007;11:171-8. [PMID: 17390169 DOI: 10.1007/s11605-006-0081-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
254 Wei SC, Tsao PN, Yu SC, Shun CT, Tsai-Wu JJ, Wu CH, Su YN, Hsieh FJ, Wong JM. Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 2005;54:666-72. [PMID: 15831913 DOI: 10.1136/gut.2004.050831] [Cited by in Crossref: 84] [Cited by in F6Publishing: 72] [Article Influence: 5.3] [Reference Citation Analysis]
255 Chen K, Gong Y, Zhang Q, Shen Y, Zhou T. Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis. Medicine (Baltimore) 2016;95:e5221. [PMID: 27861344 DOI: 10.1097/MD.0000000000005221] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
256 Konda B, Shum H, Rajdev L. Anti-angiogenic agents in metastatic colorectal cancer. World J Gastrointest Oncol. 2015;7:71-86. [PMID: 26191351 DOI: 10.4251/wjgo.v7.i7.71] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
257 Chee CE, Sinicrope FA. Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am 2010;39:601-13. [PMID: 20951919 DOI: 10.1016/j.gtc.2010.08.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
258 Ustuner Z, Meltem Akay O, Keskin M, Kuş E, Bal C, Gulbas Z. Evaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography. Med Oncol 2012;29:3125-8. [DOI: 10.1007/s12032-012-0274-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
259 Patten SG, Adamcic U, Lacombe K, Minhas K, Skowronski K, Coomber BL. VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment. BMC Cancer 2010;10:683. [PMID: 21159176 DOI: 10.1186/1471-2407-10-683] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
260 Eskens FA. Angiogenesis inhibitors in clinical development; where are we now and where are we going. Br J Cancer. 2004;90:1-7. [PMID: 14710197 DOI: 10.1038/sj.bjc.6601401] [Cited by in Crossref: 140] [Cited by in F6Publishing: 103] [Article Influence: 8.2] [Reference Citation Analysis]
261 Bolz M, Michels S, Geitzenauer W, Prager F, Schmidt-Erfurth U. Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment. Br J Ophthalmol 2007;91:785-9. [PMID: 17050580 DOI: 10.1136/bjo.2006.102467] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
262 Zoratto F, Rossi L, Zullo A, Papa A, Zaccarelli E, Tomao L, Giordani E, Colonna M, Baiano G, Tomao S. Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. Onco Targets Ther 2012;5:199-211. [PMID: 23055745 DOI: 10.2147/OTT.S30581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
263 Correale P, Cusi MG, Micheli L, Nencini C, Del Vecchio MT, Torino F, Aquino A, Bonmassar E, Francini G, Giorgi G. Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience. Invest New Drugs 2006;24:99-110. [PMID: 16502353 DOI: 10.1007/s10637-006-5932-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
264 Manne U, Shanmugam C, Katkoori VR, Bumpers HL, Grizzle WE. Development and progression of colorectal neoplasia. Cancer Biomark. 2010;9:235-265. [PMID: 22112479 DOI: 10.3233/cbm-2011-0160] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
265 Vadnais MA, Rana S, Quant HS, Salahuddin S, Dodge LE, Lim KH, Karumanchi SA, Hacker MR. The Impact of Magnesium Sulfate Therapy on Angiogenic Factors in Preeclampsia. Pregnancy Hypertens 2012;2:16-21. [PMID: 22247820 DOI: 10.1016/j.preghy.2011.08.118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
266 Blumenthal DT, Mendel L, Bokstein F. The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter? J Neurooncol 2016;127:493-502. [PMID: 26721244 DOI: 10.1007/s11060-015-2025-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
267 Snider KL, Maitland ML. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target Oncol 2009;4:67-76. [PMID: 19373440 DOI: 10.1007/s11523-009-0106-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
268 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol 2007;13:6231-5. [PMID: 18069765 DOI: 10.3748/wjg.v13.i46.6231] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
269 Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385-403. [PMID: 26775688 DOI: 10.1038/nrd.2015.17] [Cited by in Crossref: 406] [Cited by in F6Publishing: 330] [Article Influence: 81.2] [Reference Citation Analysis]
270 Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207-239. [PMID: 25782566 DOI: 10.1007/s10147-015-0801-z] [Cited by in Crossref: 379] [Cited by in F6Publishing: 257] [Article Influence: 63.2] [Reference Citation Analysis]
271 Tayama M, Furuhata T, Inafuku Y, Okita K, Nishidate T, Mizuguchi T, Kimura Y, Hirata K. Vascular endothelial growth factor 165b expression in stromal cells and colorectal cancer. World J Gastroenterol. 2011;17:4867-4874. [PMID: 22171127 DOI: 10.3748/wjg.v17.i44.4867] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
272 Hong YS, Cho HJ, Kim SY, Jung KH, Park JW, Choi HS, Oh JH, Kim BC, Sohn DK, Kim DY, Chang HJ. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer 2009;9:246. [PMID: 19619339 DOI: 10.1186/1471-2407-9-246] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
273 Ranieri G, Laface C, Laforgia M, De Summa S, Porcelli M, Macina F, Ammendola M, Molinari P, Lauletta G, Di Palo A, Rubini G, Ferrari C, Gadaleta CD. Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study. Front Oncol 2020;10:590707. [PMID: 33224885 DOI: 10.3389/fonc.2020.590707] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
274 Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007;96:1166-1169. [PMID: 17375050 DOI: 10.1038/sj.bjc.6603685] [Cited by in Crossref: 564] [Cited by in F6Publishing: 461] [Article Influence: 40.3] [Reference Citation Analysis]
275 Zhu X, Tian X, Yu C, Hong J, Fang J, Chen H. Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials. Medicine (Baltimore) 2016;95:e4232. [PMID: 27559943 DOI: 10.1097/MD.0000000000004232] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
276 Strickler JH, Hurwitz HI. Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist. 2012;17:513-524. [PMID: 22477726 DOI: 10.1634/theoncologist.2012-0003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
277 Zunder SM, van Pelt GW, Gelderblom HJ, Mancao C, Putter H, Tollenaar RA, Mesker WE. Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer. Br J Cancer 2018;119:164-9. [PMID: 29755119 DOI: 10.1038/s41416-018-0083-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
278 Cai J, Ma H, Huang F, Zhu D, Bi J, Ke Y, Zhang T. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World J Surg Oncol 2013;11:306. [PMID: 24283603 DOI: 10.1186/1477-7819-11-306] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
279 Hansen TF, Qvortrup C, Pfeiffer P. Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. Cancers (Basel) 2021;13:1031. [PMID: 33804554 DOI: 10.3390/cancers13051031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
280 Borzomati D, Nappo G, Valeri S, Vincenzi B, Ripetti V, Coppola R. Infusion of Bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treated. Updates Surg 2013;65:121-4. [DOI: 10.1007/s13304-013-0207-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
281 Lv C, Wu S, Zheng D, Wu Y, Yao D, Yu X. The Efficacy of Additional Bevacizumab to Cytotoxic Chemotherapy Regimens for the Treatment of Colorectal Cancer: An Updated Meta-Analysis for Randomized Trials. Cancer Biother Radiopharm. 2013;28:501-509. [PMID: 23768086 DOI: 10.1089/cbr.2012.1458] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
282 Press MF, Lenz HJ. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 2007;67:2045-75. [PMID: 17883287 DOI: 10.2165/00003495-200767140-00006] [Cited by in Crossref: 87] [Cited by in F6Publishing: 69] [Article Influence: 6.7] [Reference Citation Analysis]
283 Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience 2014;1:540-9. [PMID: 25594061 DOI: 10.18632/oncoscience.73] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
284 Castañeda-Gill JM, Vishwanatha JK. Antiangiogenic mechanisms and factors in breast cancer treatment. J Carcinog 2016;15:1. [PMID: 27013929 DOI: 10.4103/1477-3163.176223] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 5.2] [Reference Citation Analysis]
285 Majewska A, Wilkus K, Brodaczewska K, Kieda C. Endothelial Cells as Tools to Model Tissue Microenvironment in Hypoxia-Dependent Pathologies. Int J Mol Sci 2021;22:E520. [PMID: 33430201 DOI: 10.3390/ijms22020520] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
286 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol. 2007;13:6231-6235. [PMID: 18069765 DOI: 10.3748/wjg.13.6231] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
287 Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009;27:4821-4826. [PMID: 19752337 DOI: 10.1200/jco.2009.22.3032] [Cited by in Crossref: 103] [Cited by in F6Publishing: 48] [Article Influence: 8.6] [Reference Citation Analysis]
288 Stessels F, Van den Eynden G, Van der Auwera I, Salgado R, Van den Heuvel E, Harris AL, Jackson DG, Colpaert CG, van Marck EA, Dirix LY, Vermeulen PB. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer. 2004;90:1429-1436. [PMID: 15054467 DOI: 10.1038/sj.bjc.6601727] [Cited by in Crossref: 130] [Cited by in F6Publishing: 108] [Article Influence: 7.6] [Reference Citation Analysis]
289 Escudier B, Cosaert J, Jethwa S. Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics 2008;2:517-30. [PMID: 19707382 DOI: 10.2147/btt.s3509] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
290 Yonucu S, Yιlmaz D, Phipps C, Unlu MB, Kohandel M. Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy. PLoS Comput Biol 2017;13:e1005724. [PMID: 28922358 DOI: 10.1371/journal.pcbi.1005724] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
291 Lubezky N, Winograd E, Papoulas M, Lahat G, Shacham-Shmueli E, Geva R, Nakache R, Klausner J, Ben-Haim M. Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases. J Gastrointest Surg. 2013;17:527-532. [PMID: 23299220 DOI: 10.1007/s11605-012-2108-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
292 McCormack PL, Keam SJ. Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs. 2008;68:487-506. [PMID: 18318567 DOI: 10.2165/00003495-200868040-00009] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
293 Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Takiuchi H, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 2012;17:1-29. [PMID: 22002491 DOI: 10.1007/s10147-011-0315-2] [Cited by in Crossref: 491] [Cited by in F6Publishing: 403] [Article Influence: 49.1] [Reference Citation Analysis]
294 Wasserstrum Y, Kornowski R, Raanani P, Leader A, Pasvolsky O, Iakobishvili Z. Hypertension in cancer patients treated with anti-angiogenic based regimens. Cardiooncology 2015;1:6. [PMID: 33530150 DOI: 10.1186/s40959-015-0009-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
295 Bhattacharya A. Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs. Expert Opin Drug Deliv 2011;8:749-63. [PMID: 21473705 DOI: 10.1517/17425247.2011.571672] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
296 Pogue-Geile K, Yothers G, Taniyama Y, Tanaka N, Gavin P, Colangelo L, Blackmon N, Lipchik C, Kim SR, Sharif S, Allegra C, Petrelli N, O'Connell MJ, Wolmark N, Paik S. Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08. J Natl Cancer Inst 2013;105:989-92. [PMID: 23821759 DOI: 10.1093/jnci/djt140] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
297 Ribatti D. The inefficacy of antiangiogenic therapies. J Angiogenes Res 2010;2:27. [PMID: 21143947 DOI: 10.1186/2040-2384-2-27] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
298 Escalante CP, Chang YC, Liao K, Rouleau T, Halm J, Bossi P, Bhadriraju S, Brito-Dellan N, Sahai S, Yusuf SW, Zalpour A, Elting LS;  Epidemiology Section of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer; 2013. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer. 2016;24:4057-4074. [PMID: 27344327 DOI: 10.1007/s00520-016-3310-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
299 Chong G, Tebbutt NC. Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity. Ther Adv Med Oncol 2010;2:309-17. [PMID: 21789143 DOI: 10.1177/1758834010375096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
300 Newman JR, Helman EE, Safavy S, Zhang W, Rosenthal EL. EMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenografts. Cancer Lett 2009;274:313-8. [PMID: 18990485 DOI: 10.1016/j.canlet.2008.09.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
301 Shin SJ, Jeung HC, Ahn JB, Rha SY, Roh JK, Park KS, Kim DH, Kim C, Chung HC. A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Invest New Drugs 2010;28:650-8. [PMID: 19585083 DOI: 10.1007/s10637-009-9287-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
302 Maroun JA, Anthony LB, Blais N, Burkes R, Dowden SD, Dranitsaris G, Samson B, Shah A, Thirlwell MP, Vincent MD. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol. 2007;14:13-20. [PMID: 17576459 DOI: 10.3747/co.2007.96] [Cited by in Crossref: 91] [Cited by in F6Publishing: 51] [Article Influence: 8.3] [Reference Citation Analysis]
303 Rosa B, de Jesus JP, de Mello EL, Cesar D, Correia MM. Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis. Ecancermedicalscience 2015;9:582. [PMID: 26557880 DOI: 10.3332/ecancer.2015.582] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
304 Pai SG, Fuloria J. Novel therapeutic agents in the treatment of metastatic colorectal cancer. World J Gastrointest Oncol. 2016;8:99-104. [PMID: 26798440 DOI: 10.4251/wjgo.v8.i1.99] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
305 Moriarity A, O'Sullivan J, Kennedy J, Mehigan B, McCormick P. Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:276-293. [PMID: 27482287 DOI: 10.1177/1758834016646734] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
306 Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis. 2017;20:185-204. [PMID: 28361267 DOI: 10.1007/s10456-017-9552-y] [Cited by in Crossref: 215] [Cited by in F6Publishing: 192] [Article Influence: 53.8] [Reference Citation Analysis]
307 Yoshida I, Shiba T, Taniguchi H, Takahashi M, Murano T, Hiruta N, Hori Y, Bujo H, Maeno T. Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2014;252:1483-9. [PMID: 25030237 DOI: 10.1007/s00417-014-2717-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 3.9] [Reference Citation Analysis]